I believe we all missed the patent and reformulation issue, I’d argue because we all believed the path to clinical validation was clear, well thought through, with a high chance of success.
What we didn’t understand then, we do now.
RAC could have been a lot more transparent and clear with shareholders.
It’s funny, we are still “trusting” a very broad outlined strategy with little detail and little to zero track record. I will gladly say hindsight is 20/20 when we actually have hindsight. Right now RAC hasn’t achieved anything.
Ann: Application for quotation of securities - RAC, page-22
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.64 |
Change
-0.100(5.76%) |
Mkt cap ! $278.5M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.71 | $1.64 | $205.3K | 123.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1526 | $1.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.65 | 234 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |